- Home
- SBS vs BMRN Comparison
SBS vs BMRN Comparison
Compare SBS & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SBS
- BMRN
- Stock Information
- Founded
- SBS 1954
- BMRN 1996
- Country
- SBS Brazil
- BMRN United States
- Employees
- SBS N/A
- BMRN N/A
- Industry
- SBS Water Supply
- BMRN Biotechnology: Pharmaceutical Preparations
- Sector
- SBS Utilities
- BMRN Health Care
- Exchange
- SBS Nasdaq
- BMRN Nasdaq
- Market Cap
- SBS 13.7B
- BMRN 12.1B
- IPO Year
- SBS 2002
- BMRN 1999
- Fundamental
- Price
- SBS $21.74
- BMRN $57.50
- Analyst Decision
- SBS
- BMRN Buy
- Analyst Count
- SBS 0
- BMRN 22
- Target Price
- SBS N/A
- BMRN $93.43
- AVG Volume (30 Days)
- SBS 889.0K
- BMRN 2.2M
- Earning Date
- SBS 08-07-2025
- BMRN 08-04-2025
- Dividend Yield
- SBS 2.51%
- BMRN N/A
- EPS Growth
- SBS 184.67
- BMRN 152.82
- EPS
- SBS 2.61
- BMRN 2.71
- Revenue
- SBS $6,629,708,013.00
- BMRN $2,950,227,000.00
- Revenue This Year
- SBS N/A
- BMRN $12.23
- Revenue Next Year
- SBS $13.13
- BMRN $9.99
- P/E Ratio
- SBS $8.12
- BMRN $21.25
- Revenue Growth
- SBS 43.80
- BMRN 19.36
- 52 Week Low
- SBS $13.87
- BMRN $52.93
- 52 Week High
- SBS $22.18
- BMRN $94.85
- Technical
- Relative Strength Index (RSI)
- SBS 60.85
- BMRN 57.95
- Support Level
- SBS $21.04
- BMRN $53.76
- Resistance Level
- SBS $22.18
- BMRN $56.25
- Average True Range (ATR)
- SBS 0.39
- BMRN 1.30
- MACD
- SBS 0.08
- BMRN 0.45
- Stochastic Oscillator
- SBS 81.75
- BMRN 100.00
About SBS Companhia de saneamento Basico Do Estado De Sao Paulo - Sabesp (Each repstg 250)
Companhia De Saneamento Basico Do Estado De Sao Paulo is engaged in the provision of basic and environmental sanitation services in the Sao Paulo State and supplies treated water and sewage services on a wholesale basis. The company operates in a single segment, which is Sanitation services.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.